Surrozen Files $200M Universal Shelf, Launches New $50M At-The-Market Offering Amidst Going Concern Warning
SRZN has more than doubled off its 52-week low of $5.9.
Summary
Surrozen, Inc. filed an S-3 registration statement for a $200 million universal shelf offering and launched a new $50 million At-The-Market (ATM) program, replacing a prior one, to raise capital following a substantial net loss and a going concern warning in its recent 10-K.
Key Events · Financing and Capital Events · SRZN
-
Universal Shelf Registration Filed
Surrozen, Inc. has filed a universal shelf registration statement on Form S-3, enabling it to offer and sell various securities (common stock, preferred stock, debt, and warrants) with an aggregate offering price of up to $200,000,000 from time to time.
-
New $50M At-The-Market (ATM) Offering Launched
The company has entered into a new sales agreement with TD Securities (USA) LLC, establishing an At-The-Market (ATM) offering program to sell up to $50,000,000 of common stock. This new program replaces a prior ATM agreement dated August 29, 2025, which has been terminated.
-
Capital Raise Follows Going Concern Warning
This capital raise initiative comes on the same day as the company's 2025 10-K filing, which reported a significant net loss of $242.0 million and included a going concern warning, highlighting the critical need for additional funding to support operations.
-
Significant Potential Dilution
The potential sale of $50 million in common stock through the ATM program represents approximately 23% of the company's current market capitalization, indicating substantial potential dilution for existing shareholders. The full $200 million shelf represents over 90% of the market cap.
Analysis · SRZN · Life Sciences
This S-3 filing is a critical capital event for Surrozen, Inc., following its 2025 10-K filing on the same day which reported a substantial net loss of $242.0 million and included going concern language. The company has registered a universal shelf of up to $200 million for various securities, signaling its intent to raise significant capital. Concurrently, it has established a new At-The-Market (ATM) offering program with TD Securities (USA) LLC, allowing it to sell up to $50 million of common stock from time to time. This new ATM program replaces a prior sales agreement from August 29, 2025. The potential dilution from the $50 million ATM alone is substantial, representing approximately 23% of the current market capitalization, and the full $200 million shelf represents over 90% of the market cap. While necessary for extending the company's financial runway, this significant potential dilution and the context of the going concern warning indicate a challenging financial position.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 39.9% of the 323 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SRZN was trading at $25.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $216.3M. The 52-week trading range was $5.90 to $29.60. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.